Search
samidorphan; 3-carboxamido-4-hydroxynaltrexone
Indications:
- investigstional use in combination with buprenorphine for treatment of depression (not FDA-approved Jan 2021)
- use in combination with olanzapine for treatment of schizophrenia (FDA-approved Jan 2021) Adverse events:
- consistent with antagonism of kappa opioid receptors
- somnolence
- sedation
- dizziness
- hallucinations
Mechanism of action:
- mu opioid receptor antagonist
General
opioid receptor antagonist or narcotic antagonist
Database Correlations
PUBCHEM correlations
References
- Wikipedia: Samidorphan
https://en.wikipedia.org/wiki/Samidorphan
Component-of
olanzapine/samidorphan